Medical	0	7	O
therapy	8	15	O
for	16	19	O
intermittent	20	32	O
claudication	33	45	O
.	45	46	O

Medical	48	55	O
therapy	56	63	O
to	64	66	O
improve	67	74	O
symptoms	75	83	O
,	83	84	O
stabilise	85	94	O
the	95	98	O
underlying	99	109	O
vascular	110	118	O
disease	119	126	O
and	127	130	O
improve	131	138	O
lower	139	144	B-Organism_subdivision
limb	145	149	I-Organism_subdivision
outcomes	150	158	O
is	159	161	O
an	162	164	O
important	165	174	O
and	175	178	O
effective	179	188	O
adjunct	189	196	O
to	197	199	O
lifestyle	200	209	O
modification	210	222	O
and	223	226	O
surgical	227	235	O
or	236	238	O
endovascular	239	251	O
interventions	252	265	O
in	266	268	O
patients	269	277	B-Organism
with	278	282	O
IC	283	285	O
.	285	286	O

Randomised	287	297	O
placebo	298	305	O
controlled	306	316	O
trials	317	323	O
have	324	328	O
shown	329	334	O
that	335	339	O
the	340	343	O
phosphodiesterase	344	361	B-Gene_or_gene_product
III	362	365	I-Gene_or_gene_product
inhibitor	366	375	O
cilostazol	376	386	B-Drug_or_compound
100mg	387	392	O
bid	393	396	O
improves	397	405	O
pain	406	410	O
-	410	411	O
free	411	415	O
and	416	419	O
maximum	420	427	O
walking	428	435	O
distance	436	444	O
,	444	445	O
as	446	448	O
well	449	453	O
as	454	456	O
quality	457	464	O
of	465	467	O
life	468	472	O
,	472	473	O
in	474	476	O
a	477	478	O
range	479	484	O
of	485	487	O
patients	488	496	B-Organism
with	497	501	O
intermittent	502	514	O
claudication	515	527	O
in	528	530	O
whom	531	535	O
there	536	541	O
is	542	544	O
no	545	547	O
evidence	548	556	O
of	557	559	O
tissue	560	566	B-Tissue
necrosis	567	575	O
or	576	578	O
rest	579	583	O
pain	584	588	O
.	588	589	O

This	590	594	O
review	595	601	O
summarises	602	612	O
the	613	616	O
evidence	617	625	O
from	626	630	O
8	631	632	O
pivotal	633	640	O
trials	641	647	O
of	648	650	O
cilostazol	651	661	B-Drug_or_compound
involving	662	671	O
over	672	676	O
2000	677	681	O
patients	682	690	B-Organism
with	691	695	O
intermittent	696	708	O
claudication	709	721	O
treated	722	729	O
for	730	733	O
up	734	736	O
to	737	739	O
6	740	741	O
months	742	748	O
.	748	749	O

There	750	755	O
is	756	758	O
comparatively	759	772	O
less	773	777	O
evidence	778	786	O
to	787	789	O
support	790	797	O
the	798	801	O
use	802	805	O
of	806	808	O
other	809	814	O
treatment	815	824	O
modalities	825	835	O
for	836	839	O
relief	840	846	O
of	847	849	O
symptoms	850	858	O
in	859	861	O
intermittent	862	874	O
claudication	875	887	O
,	887	888	O
but	889	892	O
there	893	898	O
is	899	901	O
considerable	902	914	O
interest	915	923	O
in	924	926	O
therapeutic	927	938	O
angiogenesis	939	951	O
to	952	954	O
promote	955	962	O
new	963	966	O
vessel	967	973	B-Multi-tissue_structure
formation	974	983	O
and	984	987	O
enhance	988	995	O
collateralisation	996	1013	O
of	1014	1016	O
the	1017	1020	O
lower	1021	1026	B-Organism_subdivision
limb	1027	1031	I-Organism_subdivision
using	1032	1037	O
recombinant	1038	1049	O
growth	1050	1056	O
factor	1057	1063	O
proteins	1064	1072	O
or	1073	1075	O
gene	1076	1080	O
transfer	1081	1089	O
strategies	1090	1100	O
.	1100	1101	O

The	1102	1105	O
rationale	1106	1115	O
for	1116	1119	O
therapeutic	1120	1131	O
angiogenesis	1132	1144	O
is	1145	1147	O
discussed	1148	1157	O
,	1157	1158	O
together	1159	1167	O
with	1168	1172	O
the	1173	1176	O
most	1177	1181	O
recent	1182	1188	O
results	1189	1196	O
from	1197	1201	O
randomised	1202	1212	O
trials	1213	1219	O
in	1220	1222	O
patients	1223	1231	B-Organism
with	1232	1236	O
peripheral	1237	1247	O
arterial	1248	1256	O
disease	1257	1264	O
.	1264	1265	O

